Jianjun Xu

USPTO Granted Patents = 40 (Patent Applications = 4)

CIPO Patents = 8 (Patent Applications = 3)

EPO Patents = 19 (Patent Applications = 20)

Average Co-Inventor Count = 8.1

ph-index = 13

Forward Citations = 382(Granted Patents)

Location History:

Branford, CT (US) (2010 - 2017)
Madison, CT (US) (2013 - 2019)
Seattle, WA (US) (2017 - 2020)
Belevue, WA (US) (2022)
Bellevue, WA (US) (2018 - 2023)

Company Filing History:

16 out of 30

Gilead Connecticut, Inc.

patents

15 out of 919

Gilead Sciences, Inc.

Cgi Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2010-2025

Loading Chart...

40 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12358903 - FXR (NR1H4) modulating compounds (2025-07-15),

2. 12263163 - Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor (2025-04-01),

3. 11739065 - FXR (NR1H4) modulating compounds (2023-08-29),

4. 11517570 - Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine (2022-12-06),

5. 11247986 - FXR (NR1H4) modulating compounds (2022-02-15),

6. 10981881 - FXR (NR1H4) modulating compounds (2021-04-20),

7. 10842803 - Imidazopyridines Syk inhibitors (2020-11-24),

8. 10828299 - Crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine (2020-11-10),

9. 10774054 - FXR (NR1H4) modulating compounds (2020-09-15),

10. 10421730 - FXR (NR1H4) modulating compounds (2019-09-24),

11. 10344040 - Pyridone and aza-pyridone compounds and methods of use (2019-07-09),

12. 10342794 - Substituted imidazo[1,2-a]pyrazines as Syk inhibitors (2019-07-09),

13. 10329286 - FXR (NR1H4) modulating compounds (2019-06-25),

14. 10093684 - Substituted imidazo[1,2-a]pyrazines as Syk inhibitors (2018-10-09),

15. 10092583 - Imidazopyridines Syk inhibitors (2018-10-09),

Certainly! Here is an article about inventor Jianjun Xu:

Title: Innovator Spotlight: Jianjun Xu - Pioneering Pharmaceutical Solutions

Introduction:

Jianjun Xu, a prolific inventor based in Madison, CT, has made significant contributions to the field of pharmaceuticals with over 38 patents to his name. His innovative work focuses on developing compounds that have the potential to revolutionize the treatment of various diseases and conditions.

Latest Patents:

1. FXR (NR1H4) Modulating Compounds: Jianjun Xu's latest patent revolves around compounds that bind to the NR1H4 receptor (FXR) and function as agonists. These compounds show promise in the treatment of diseases by binding to this nuclear receptor, paving the way for the development of novel medicaments.

2. Crystalline Succinate Salt Compound: Another recent patent by Jianjun Xu is related to Syk inhibitors, significant for their potential in treating cancer and inflammatory conditions. The patent outlines the synthesis of a crystalline monomesylate salt of a specific compound, showcasing Xu's expertise in drug development.

Career Highlights:

Jianjun Xu has honed his craft while working at renowned pharmaceutical companies such as Gilead Connecticut, Inc. and Gilead Sciences, Inc. His experience in these esteemed organizations has played a pivotal role in shaping his innovative approach towards drug discovery and development.

Collaborations:

During his career, Jianjun Xu has collaborated with accomplished professionals in the field. Notable coworkers include Peter A Blomgren and Kevin S Currie, who have worked alongside Xu, contributing to the success of various projects and patents.

Conclusion:

In conclusion, Jianjun Xu stands as a leading figure in the realm of pharmaceutical innovations, with a remarkable track record of patents that have the potential to transform healthcare. His dedication to developing groundbreaking compounds underscores his commitment to advancing the field of medicine and improving patient outcomes worldwide.

This text is generated by artificial intelligence and may not be accurate.